In tough economic times, many companies are forced to downsize, trim budgets and preserve profit margins, while expecting a leaner, meaner organisation to survive the tempest. The reality is that the changes leave fewer people to accomplish the same amount of work on less marketing dollars; productivity becomes the new name of the game. This [...]
Entries Tagged as 'brain cancer'
Increasing importance of competitive intelligence in bear markets
October 18th, 2008 · No Comments · Market research, biotech, brain cancer, competitive intelligence, marketing, oncology, pharma
Tags:
Cediranib (AZD2171) in Glioblastoma and brain cancer
July 14th, 2008 · No Comments · FGF, Tie-2, brain cancer, cancer, competitive intelligence, glioblastoma, market intelligence, market trends, oncology
The investigational drug AZD2171 (cediranib) from Astra-Zeneca may help shrink tumours and prolong survival of patients with a relatively common, aggressive type of brain cancer. In a phase II study of 31 patients with recurrent glioblastoma, researchers observed that daily treatment with cediranib decreased tumour volume by more than half in 56 percent of patients. [...]
Tags: